WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below.  Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare ConferenceLocation: N ...

WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare ConferenceLocation: Ne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40708 CLIMB BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83-2273741 (State or other jurisdiction of i ...

Exhibit 99.1 Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks • Continued development of subcutaneous (SC) formulation. Climb Bio obtained supportive non-clinical data for its budoprutug SC formulation, which demonstrated high bioavailability and favorable toler ...

Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated ...

WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company’s 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was grante ...

Financial Performance - Climb Bio, Inc. reported a net loss of $20.8 million for Q1 2025, compared to a net loss of $1.7 million for Q1 2024, resulting in an accumulated deficit of $250.7 million as of March 31, 2025[127]. - Total operating expenses for Q1 2025 were $23.0 million, compared to $3.0 million in Q1 2024, reflecting a 666.0% increase[150]. - The net loss for Q1 2025 was $20.8 million, significantly higher than the $1.7 million loss in Q1 2024, marking an increase of 1124.6%[150]. - Net cash used in operating activities for Q1 2025 was $15.4 million, compared to $1.8 million in Q1 2024[164]. - Net cash used in investing activities for Q1 2025 was $42.8 million, primarily due to $58.8 million in marketable securities purchases[167]. - Interest income increased from $1.3 million in Q1 2024 to $2.3 million in Q1 2025, a growth of 70.5%[154]. - Foreign currency loss increased from $33,000 in Q1 2024 to $50,000 in Q1 2025, reflecting a 51.5% rise[153]. Cash and Funding - The company has cash, cash equivalents, and marketable securities of $197.8 million as of March 31, 2025, which is projected to fund operations through 2027[128]. - Cash, cash equivalents, and marketable securities as of March 31, 2025, were $197.8 million, down from $212.5 million as of December 31, 2024[155]. Research and Development - Research and development expenses for Q1 2025 totaled $17.3 million, a significant increase from $1.1 million in Q1 2024[140]. - Climb Bio, Inc. anticipates substantial increases in research and development expenses as it conducts ongoing clinical trials and studies[142]. - The company has paused the development of its Kv7 program, previously focused on neuronal excitability disorders, while seeking a partner for further development[126]. - The Mabworks Agreement for CLYM116 included an upfront payment of $9.0 million, with additional milestone payments and royalties expected[134]. - Research and development expenses increased from $1.1 million in Q1 2024 to $17.3 million in Q1 2025, a rise of 1488.2%[151]. Product Development - Budoprutug, the cornerstone product candidate, showed a 60% complete remission rate in a Phase 1b trial for primary membranous nephropathy (pMN)[124]. - Climb Bio, Inc. received FDA clearance for a Phase 2 clinical trial of budoprutug in pMN, with patient dosing anticipated in the second half of 2025[124]. - The company is also developing CLYM116, with preclinical data expected in the second half of 2025 and an IND submission planned for the same period[125]. Corporate Actions - The acquisition of Tenet Medicines, Inc. was completed for $52.8 million, including $41.9 million in common stock and $10.8 million in transaction costs and loans[133]. Administrative Expenses - General and administrative expenses rose from $1.9 million in Q1 2024 to $5.7 million in Q1 2025, an increase of 197.3%[152]. Company Classification - The company is classified as an emerging growth company under the JOBS Act, allowing it to delay adopting new accounting standards until they apply to private companies[174]. - The company will remain an emerging growth company until it reaches total annual gross revenue of $1.235 billion or more, issues more than $1.0 billion of non-convertible debt, becomes a "large accelerated filer" with at least $700.0 million of outstanding equity securities, or until December 31, 2026[175]. - The consolidated financial statements may not be comparable to those of companies that comply with new accounting pronouncements as of public company effective dates[175]. - As a smaller reporting company, the company is not required to provide certain market risk disclosures[176].

Financial Performance - Climb Bio reported cash, cash equivalents, and marketable securities of $197.8 million as of March 31, 2025, expected to fund operations through 2027[8] - Research and Development (R&D) expenses for Q1 2025 were $17.3 million, significantly up from $1.1 million in Q1 2024[8] - General and Administrative (G&A) expenses for Q1 2025 were $5.7 million, compared to $1.9 million in Q1 2024[8] - The net loss for Q1 2025 was $20.8 million, with a net loss per share of $0.31, compared to a net loss of $1.7 million and $0.06 per share in Q1 2024[8] Clinical Trials and Regulatory Approvals - Climb Bio received FDA clearance for a Phase 2 clinical trial of budoprutug in primary membranous nephropathy (pMN) and a Phase 1b/2a trial in immune thrombocytopenia (ITP) in March 2025[4] - The company plans to initiate clinical studies for budoprutug in ITP and systemic lupus erythematosus (SLE) in the coming weeks, with pMN studies expected to start in the second half of 2025[3] - Climb Bio is pursuing regulatory clearance for budoprutug clinical trials in SLE outside the United States[4] Pipeline and Development Plans - Climb Bio's pipeline includes budoprutug and CLYM116, targeting immune-mediated diseases with significant therapeutic potential[7] - Climb Bio is advancing the CLYM116 program, with plans to submit an investigational new drug (IND) or clinical trial application (CTA) by year-end 2025[3] Leadership Changes - The company appointed Kim Cobleigh Drapkin and Bo Cumbo as Independent Directors, and Perrin Wilson, Ph.D., as Chief Business Officer in 2025[8]

Core Insights - Climb Bio, Inc. has appointed Kim Cobleigh Drapkin and Bo Cumbo as independent directors, enhancing its leadership team with experienced professionals from the biotechnology sector [1][2][3] Company Developments - Kim Cobleigh Drapkin will serve as the Audit Committee Chair, while Bo Cumbo will take on the role of Compensation Committee Chair [1] - The appointments are expected to provide valuable insights as Climb Bio advances its pipeline and transitions into a late-stage, pre-commercial company focused on immune-mediated diseases [2] Leadership Background - Kim Cobleigh Drapkin has over 30 years of experience in the biotechnology and pharmaceutical industries, previously serving as CEO of Graphite Bio and CFO at Jounce Therapeutics [2][3] - Bo Cumbo also brings over 30 years of experience, having led successful commercial launches for 11 specialty and rare disease therapies, and currently serves as CEO of Solid Biosciences [3] Board Changes - Simon Tate will step down from the Board, and Adam Rosenberg will not seek re-election at the 2025 Annual Meeting of Stockholders [4] Company Overview - Climb Bio is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, with a pipeline that includes budoprutug and CLYM116 [5]

Core Insights - Climb Bio, Inc. will participate in the 24th Annual Needham Healthcare Conference, which will be held virtually from April 7-10, 2025 [1] - The conference will include presentations and one-on-one investor meetings, with Climb Bio's presentation scheduled for April 10, 2025, at 8:45 a.m. ET [2] Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases [2] - The company's pipeline includes budoprutug, an anti-CD19 monoclonal antibody that has shown B-cell depletion and potential applications for a variety of B-cell mediated diseases [2] - Another key product in development is CLYM116, an anti-APRIL monoclonal antibody currently undergoing IND-enabling studies for IgA nephropathy [2]